エピソード

  • Malaria Vaccine Advances: Togo Launches Nationwide Distribution, Uganda Accelerates Rollout, and Innovative Approaches Emerge

    Malaria Vaccine Advances: Togo Launches Nationwide Distribution, Uganda Accelerates Rollout, and Innovative Approaches Emerge
    2025/09/09
    Recent developments in malaria prevention have drawn global attention, with significant advances in both vaccine distribution and research. On September 1, Togo marked a milestone by launching nationwide distribution of the malaria vaccine, a major step intended to reduce child mortality due to malaria. This nationwide rollout positions Togo among the leading African countries making large-scale investments in immunization strategies, aiming to protect children under five—the demographic most vulnerable to malaria-related deaths, according to the Malaria Consortium.

    Meanwhile, Uganda is accelerating its malaria vaccination programme, as reported by Gavi. Efforts in Uganda are focused on expanding community outreach and improving vaccine delivery logistics, with authorities noting increasing uptake rates in recent weeks. The expanded vaccination programme is expected to make a significant impact on malaria incidence, especially in high-risk districts.

    Research continues to underline both the promise and limitations of current malaria vaccines. Nature notes that although vaccines such as RTS,S and R21/Matrix-M are essential tools, their efficacy is still challenged by the complex lifecycle of the Plasmodium parasite and gaps in collective understanding of the immune response required to confer long-term protection. Scientists are racing not only to improve efficacy but also to develop products that are simpler to administer and more robust in endemic regions.

    Recent deployments in Mali involve a revised dosing regimen for the malaria vaccine, targeting children ages 3 to 5 with a schedule of three doses spread across the malaria season. The Borgen Project reports that this new strategy was adopted based on the region’s specific transmission patterns, optimising protection and reducing the frequency of health facility visits required for booster shots.

    Innovative approaches are also emerging. Drug Discovery News details the potential of L9LS, a monoclonal antibody, which stands out for its ability to confer protection via a single dose that lasts up to six months. This could greatly simplify prevention efforts, particularly for seasonal malaria regions, and reduce the logistical challenges associated with multi-dose vaccine regimens. However, experts caution that monoclonal antibodies and vaccines face barriers to deployment, particularly insufficient funding and the ongoing need for sustained investment in research and infrastructure.

    On September 8, the University of Maryland School of Medicine announced the appointment of Dr. Stefan Kappe as the new director of its Center for Vaccine Development and Global Health. Dr. Kappe’s research has focused on candidate vaccines capable of providing higher levels of protection against malaria, and his leadership is expected to drive further innovation in vaccine development and clinical trials.

    Amid these advances, funding remains a critical issue. According to Drug Discovery News, gaps left by temporary interruptions in international health programs, such as the US President’s Malaria Initiative, continue to threaten progress. Restoring and increasing investment will be necessary to keep pace with research needs and ensure newly developed approaches are accessible to the communities that need them most.

    Overall, the past two days have witnessed an increased focus on the operational aspects of malaria vaccination—new strategies for distribution and dosing, the emergence of antibody-based prevention, and renewed advocacy for sustained financial and scientific commitment. As various African nations roll out and refine their vaccine programmes and international research efforts highlight both progress and ongoing challenges, the future of malaria prevention appears to rely on a careful blend of innovation, policy, and persistent investment.
    続きを読む 一部表示
    4 分
  • Togo Leads the Charge: Malaria Vaccine Rollout Brings Hope for Africa's Disease-Free Future

    Togo Leads the Charge: Malaria Vaccine Rollout Brings Hope for Africa's Disease-Free Future
    2025/09/07
    Togo this week marked a critical milestone in the global fight against malaria, becoming the latest country to introduce the R21/Matrix-M malaria vaccine into its national immunization program. According to the Ecofin Agency, the campaign began on September 1, 2025, and targets approximately 269,000 children across all 39 health districts in the country. The focus is on children under five, who account for the majority of malaria cases and deaths locally. The Health and Public Hygiene Minister, Tchin Darré, emphasized that the program aims to liberate communities from the grip of malaria by 2030, enabling them to contribute effectively to the country's development. This widespread initiative is possible thanks to a partnership involving the Togolese government, WHO, UNICEF, Gavi, and other partners.

    The R21/Matrix-M vaccine campaign in Togo represents a significant step forward in malaria prevention on the African continent, as Togo joins countries like Ghana, Benin, and Nigeria in vaccine adoption. Togofirst.com reports that the vaccine, delivered in a four-dose schedule between the ages of 5 and 15 months, is expected to reach annual coverage rates of 80% for the first dose and 70% for the completion dose. Health officials aim to cut malaria-related child morbidity and mortality by 65% by 2030. For Togo, where the disease accounts for 40% of outpatient consultations and 25% of hospital admissions, especially affecting children, the campaign represents an essential public health response.

    However, the challenge extends beyond vaccine rollout. Health authorities underscore the importance of community engagement, tackling misinformation, and securing adequate resources to ensure sustainable success. The government will need to persuade parents to participate, dispel rumors about vaccination, and maintain logistical and financial support over the years ahead.

    Meanwhile, innovation in malaria vaccine development continues to accelerate globally. On September 4, 2025, Acuitas Therapeutics announced significant progress in developing an mRNA-based vaccine against Plasmodium vivax malaria, a different but highly significant strain of the parasite. According to the company, their clinical studies have demonstrated strong protection, adding a promising new tool to the fight against malaria.

    Yet, scientific challenges remain, especially in regions where other parasitic diseases, such as helminth infections, are common. Researchers like Dr. Rajagopal Murugan, who has recently received an ERC starting grant as highlighted by Leiden University Medical Center, are investigating how these co-infections may undermine the effectiveness of malaria vaccines. Murugan’s research aims to identify where the immune response breaks down and to find solutions tailored for populations most at risk.

    All of these developments occur against a backdrop of a complex threat. Malaria remains endemic across large swathes of sub-Saharan Africa, with transmission and disease burden surging during rainy seasons. In Togo alone, official statistics from the Ministry of Health show that in 2022, children under five represented 64% of confirmed cases and 65% of hospital deaths linked to malaria.

    In light of the recent breakthroughs and ongoing challenges, global health agencies and researchers are focused both on enlarging vaccine access and on refining scientific approaches to ensure malaria elimination is achievable for every community.
    続きを読む 一部表示
    4 分
  • Malaria Vaccine Rollout Gains Momentum in Africa, Saving Lives

    Malaria Vaccine Rollout Gains Momentum in Africa, Saving Lives
    2025/09/02
    Recent days have seen several significant developments in the fight against malaria, particularly concerning the rollout and integration of the malaria vaccine across parts of Africa. Malaria, a life-threatening disease caused by parasites transmitted through the bites of infected female Anopheles mosquitoes, remains a dominant public health challenge in sub-Saharan Africa. Experts estimate that the disease continues to kill hundreds of thousands annually, with children under five enduring the highest risk of severe illness and death.

    On September 1, 2025, Togo officially introduced the R21 malaria vaccine into its national immunization program, marking a major milestone in the country’s public health strategy. The Ministry of Health and Hygiene’s immunization division led the initiative, emphasizing broad awareness and mobilization at a recent stakeholder meeting in Lomé. Authorities outlined that children five months and older will now systematically receive four doses of the vaccine: at five, six, seven, and fifteen months of age. The government advocates the vaccine as both safe and effective, aiming to reduce the incidence of simple and severe malaria cases among children. The R21 vaccine’s rollout is supported by the Global Alliance for Vaccines (Gavi), and executive-level meetings have reinforced partnerships at the highest political level, including recent discussions between Gavi’s CEO Sania Nishtar and Togolese President Faure Gnassingbé during the Tokyo International Conference on African Development. According to local health officials, these efforts are integrated within broader malaria prevention measures including treated mosquito nets and chemoprevention for pregnant women, reflecting a commitment to comprehensive disease control.

    Simultaneously, Western Equatoria State in South Sudan is launching its first malaria vaccination campaign for children under five, spearheaded by the government in partnership with organizations such as UNICEF, World Vision, and CMMB. The campaign introduces a multi-dose regimen beginning at six months of age, followed by doses at seven, eight, and eighteen months. Health leaders in the region have stressed that malaria remains the foremost threat to child health, citing staggering statistics: in 2022, South Sudan recorded over 2.8 million malaria cases, and at least 18 children reportedly die from the disease each day. Officials describe these deaths as preventable, urging expanded vaccination coverage and support for harder-to-reach communities.

    The World Health Organization and other global agencies continue to monitor and support malaria prevention strategies, including vaccine deployment. The organization notes that malaria vaccines such as Mosquirix and R21/Matrix-M are now available in several African countries, though not currently in the U.S., reflecting the regional focus of the rollout. Routine immunization programs are being adjusted to accommodate the malaria vaccine, and significant investments in training and distribution are ensuring that doses reach tens of thousands of children in the areas most in need.

    These initiatives come at a time when vaccine-preventable diseases continue to threaten global health and development. The World Health Organization, the UK Health Security Agency, and other institutions emphasize staying up to date on disease outbreaks and vaccination schedules, especially for those traveling to affected regions. As efforts intensify across Togo, South Sudan, and other African nations, government leaders and health partners remain united in their mission to ensure every eligible child receives the protective benefit of malaria vaccination. The recent actions underscore a renewed commitment to reducing child mortality and confronting malaria’s persistent grip on communities during peak transmission seasons.
    続きを読む 一部表示
    4 分
  • Urgent Call to Action: African Ministers Demand Accelerated Malaria Fight as Vaccine Rollout Gains Momentum

    Urgent Call to Action: African Ministers Demand Accelerated Malaria Fight as Vaccine Rollout Gains Momentum
    2025/08/29
    African health ministers meeting in Lusaka, Zambia this week have issued a strong call for accelerated action in the fight against malaria, warning that current efforts are not reducing cases and deaths fast enough. The ministers gathered for the Seventy-fifth session of the World Health Organization (WHO) Regional Committee for Africa from August 25 to 27, where they highlighted successes but also significant challenges in malaria control. According to the WHO Regional Office for Africa, over the past two decades malaria prevention measures have averted an estimated 2.2 billion cases and 12.7 million deaths across the continent. Despite these gains, malaria continues to claim hundreds of thousands of lives each year in Africa, particularly among children under five.

    One of the key topics of discussion was the ongoing rollout and scale-up of malaria vaccines. By July 2025, close to six million children had received a malaria vaccine in 20 countries, marking a major step forward in prevention. The introduction of this vaccine is widely viewed as a game changer, complementing other interventions such as insecticide-treated bed nets and seasonal malaria chemoprevention. WHO Regional Director for Africa Dr Mohamed Janabi emphasized the urgency of ramping up coverage, stating that ending malaria would not only save lives but also drive economic growth and stability.

    Efforts to boost Africa’s capacity for vaccine research, development, and production received a boost this week with a new Memorandum of Understanding signed between WHO Africa and the International Vaccine Institute. As reported by the WHO, this new partnership aims to increase vaccine equity, support local manufacturing, and strengthen health innovation across the continent. Dr Jerome Kim, Director General of the International Vaccine Institute, noted that the agreement marks a new phase of leadership in vaccine innovation, including for malaria vaccines. The collaboration is expected to facilitate technology transfer, harmonize regulatory standards, and build regional expertise in vaccinology and biomanufacturing.

    Research groups such as Target Malaria have reaffirmed their commitment to developing innovative interventions against malaria, including genetic technologies to modify mosquitoes and reduce transmission. In a public statement released August 28, Target Malaria stressed the need for integrating new tools alongside vaccines, and highlighted the importance of responsible, community-engaged research tailored to Africa’s context. The group receives significant support from institutions such as the Gates Foundation and partners across Africa and Europe.

    Despite these scientific advances, malaria control faces looming challenges from global funding shortfalls. According to Think Global Health, this year’s global funding for malaria and other infectious disease control is under strain, with Gavi, the Vaccine Alliance, and other organizations facing cuts due to major donors including the United States pulling back support. The Global Fund to Fight AIDS, Tuberculosis and Malaria will seek $18 billion at its upcoming replenishment conference but donor fatigue and shifting international priorities pose risks to sustained progress, especially in sub-Saharan Africa where the disease burden remains highest.

    Amid these mixed signals, health leaders stressed that continued investment and coordinated action are vital, especially as some countries show what is possible: Algeria in 2019 and Cabo Verde in 2024 were both certified malaria-free, and Rwanda and Sao Tome and Principe are on track to hit 2025 targets. The consensus from experts and policymakers alike is clear—malaria can be consigned to history, but only if the momentum on vaccines, research, and funding is not just maintained, but intensified.
    続きを読む 一部表示
    4 分
  • Malaria Vaccine Rollout Sweeps Across Africa, Aiming to Save Millions of Children

    Malaria Vaccine Rollout Sweeps Across Africa, Aiming to Save Millions of Children
    2025/08/22
    Africa is witnessing a historic moment in the fight against malaria, as several countries expand their routine childhood immunization programs to include malaria vaccines, a move experts believe could dramatically reduce child deaths on the continent. According to Nature, Uganda launched the continent’s largest malaria vaccine rollout in March 2025, distributing over two million doses of the R21/Matrix-M vaccine to 105 districts and targeting more than a million children under the age of two. This major initiative is backed by Gavi, the Vaccine Alliance, the World Health Organization, and UNICEF, and it marks Uganda’s determination to integrate the four-dose vaccine into its regular health system while continuing traditional measures like bed nets and indoor spraying.

    Other African nations are quickly following suit. Guinea just added the RTS,S malaria vaccine to its standard childhood immunization regimen, with free access for infants aged 5 to 11 months in four highly affected districts, as announced by DevelopmentAid on August 20, 2025. Guinea’s Health Minister called this addition a “historic step forward,” noting that the vaccine’s introduction is crucial in a country where malaria is responsible for more than a third of all hospital visits and remains the leading killer of children under five. UNICEF has delivered more than half a million vaccine doses and trained healthcare workers, with public awareness efforts rolling out on radio and television. Previous data from countries such as Ghana, Kenya, and Malawi — where the vaccine is already in use — shows a significant reduction in malaria-related hospitalizations and deaths.

    Nigeria’s Kebbi State is seeing promising early results from the malaria vaccine campaign, according to a Gavi report from August 15, 2025. Healthcare workers there describe a notable drop in daily malaria cases among children since the introduction of the vaccine, which has eased the burden on overstretched clinics and caregivers. The hope is that these benefits will expand as coverage increases.

    There is also important innovation in malaria prevention campaigns. Médecins Sans Frontières and Chadian health officials are experimenting with integrating the R21 vaccine into routine seasonal malaria chemoprevention programs, especially targeting regions with highly seasonal malaria transmission. As reported by MSF on August 21, 2025, the aim is to both protect children and compare approaches for maximizing the impact of new vaccines. Clinical trials indicate both the R21 and RTS,S vaccines reduce malaria cases by more than 50% in the first year after vaccination.

    In addition to vaccines, a breakthrough treatment for the youngest patients is on the horizon. The Africa CDC announced on August 16, 2025, that Switzerland has approved a new artemether-lumefantrin formulation tailored specifically for newborns and infants under five kilograms—a group that previously had no approved safe treatment options. The new medicine dissolves in breast milk with a sweet flavor, greatly improving ease of administration for infants. Rapid regulatory approval is expected in several African countries, thanks to collaborative trials and expedited review processes.

    Experts, including those at Africa CDC, highlight that these rapid developments in both prevention and treatment mark a turning point, but stress that vaccines and new drugs are meant to complement—not replace—established measures like bed nets, spraying, and prompt medical care. According to the latest World Health Organization report, malaria killed nearly 600,000 people in 2023, with 95 percent of these deaths occurring in Africa and the majority among children under five. With new tools becoming available and deployment accelerating, public health authorities across Africa express optimism that these efforts could bring the continent closer to a malaria-free future within a generation.
    続きを読む 一部表示
    4 分
  • Breakthrough Malaria Defenses: Vaccines, Drugs, and Transmission Blocking Strategies Advance Globally

    Breakthrough Malaria Defenses: Vaccines, Drugs, and Transmission Blocking Strategies Advance Globally
    2025/08/12
    Global efforts against malaria saw a flurry of developments in the past 48 hours, led by new science on vaccines, fresh trial plans in Asia, and program updates from Africa. Researchers also reported advances in antimalarial drugs that could complement vaccination campaigns.

    On the science front, two separate announcements converged on how to stop the parasite at different stages of its life cycle. Medical Xpress reports that new immunology data explain why the WHO‑recommended R21/Matrix‑M vaccine protects so effectively at the earliest stage of infection: antibodies elicited by R21 closely mimic those produced after natural infection, targeting the sporozoite form transmitted by mosquito bites. The study, published in the Journal of Experimental Medicine and led by Texas Biomedical Research Institute in collaboration with the University of Oxford’s Jenner Institute, helps clarify how R21 blocks the parasite before it reaches the bloodstream, the point at which symptoms begin, and underscores the role of the Matrix‑M adjuvant in boosting that response, according to Medical Xpress.

    A complementary strategy—blocking transmission inside the mosquito—is advancing as well. Drug Target Review reports that Australian scientists at the Walter and Eliza Hall Institute have, for the first time, visualized a key malaria parasite fertilization complex using cryo‑electron microscopy, enabling the design of an mRNA vaccine candidate that induces antibodies to stop parasite reproduction in mosquitoes. According to Drug Target Review, this next‑generation approach aims to cut transmission by preventing the parasite from fertilizing and spreading within the vector, potentially breaking the human–mosquito cycle.

    In Southeast Asia, Indonesia is preparing to test whether one vaccination regimen can protect against the two most widespread human malaria species. OUCRU (the Oxford University Clinical Research Unit) announced plans for a Phase 2 clinical trial in Keerom, Papua, that will co‑administer Oxford’s R21 for Plasmodium falciparum and the related Rv21 candidate for Plasmodium vivax. OUCRU notes this will be the first human trial of a dual‑species malaria vaccination strategy and, if successful, could be game‑changing for the Asia‑Pacific, where the burden of P. vivax remains high. The long‑term aim, OUCRU adds, is a single vaccination that protects against both species.

    On the implementation side, vaccine rollout continues to expand in high‑burden settings. ReliefWeb reports that South Sudan has launched the second phase of its R21 malaria vaccine introduction across 52 counties to protect children. From July 2024 to May 2025, 148,878 children received a first dose, and authorities are working to accelerate coverage as the program scales, according to ReliefWeb. The update reflects growing momentum behind the WHO‑recommended vaccines for pediatric prevention in Africa.

    Meanwhile, drug development efforts may soon bolster first‑line therapies threatened by resistance. News‑Medical reports that chemists at the University of California, San Francisco have re‑engineered a next‑generation antimalarial scaffold to improve solubility and oral dosing without sacrificing potency. The optimized compound matched the activity of the prior candidate artefenomel and outperformed artemisinin against artemisinin‑resistant parasites in preclinical tests, according to News‑Medical. The work, published in Science Advances, points to potential successors to current treatments that could be affordable and amenable to combination regimens.

    Together, these updates sketch a multipronged strategy: R21 continues to show why it works in children by mimicking natural immunity against sporozoites, WEHI’s structural biology is powering transmission‑blocking mRNA vaccine candidates targeted inside mosquitoes, OUCRU is moving toward dual‑species protection in Indonesia, South Sudan is broadening pediatric rollout, and UCSF’s chemistry advances could strengthen the therapeutic backbone as resistance evolves.
    続きを読む 一部表示
    4 分
  • "Breakthrough Malaria Treatments and Vaccines Advance Globally, but Funding Gaps and Inequities Persist"

    "Breakthrough Malaria Treatments and Vaccines Advance Globally, but Funding Gaps and Inequities Persist"
    2025/08/10
    Malaria remains a global health challenge, and in recent days, several developments have emerged in both the fight against the disease and the ongoing rollout of vaccines. On August 8, it was reported by The World that Ghana has approved the world's first malaria drug specifically for newborns. The medication, called Coartem Baby, is the result of nearly a decade of research and dissolves in breast milk, making it both safe and effective for infants. This marks a major advance in infant malaria care, yet concerns remain as US funding cuts have put crucial malaria research in Africa at risk, leaving experts in Ghana alarmed over a $10 million gap in their malaria elimination budget.

    In Uganda, the fight against malaria intensified earlier this year. Seed Global Health highlighted ongoing efforts since April 2025 to integrate the malaria vaccine into child immunization schedules across 105 districts identified with high or moderate transmission. Uganda ranks third in malaria burden among African nations—according to the latest WHO report—and the inclusion of the vaccine is expected to make a significant impact on child mortality and public health. The country’s campaign emphasizes not only delivering the vaccine but also training health workers to build trust within communities and educate caregivers.

    Elsewhere on the continent, Rwanda is reconsidering the use of malaria vaccines after a surprise surge in cases following years of progress, as Malaria World reported on August 6. This renewed evaluation includes vaccines that the country had previously declined, showing a growing willingness to adopt new preventive measures as the situation evolves.

    Globally, vaccine research continues to push boundaries. On August 7, Malaria World published findings of a new bivalent viral vectored malaria vaccine—the m8Δ vaccine—which offers protection against both Plasmodium falciparum and Plasmodium vivax, effectively targeting two of the most dangerous malaria parasites. This advance is joined by another significant stride announced by WEHI, where researchers used cryo-electron microscopy to reveal a previously unknown region in the malaria parasite’s fertilization complex. Their work identified new domains on proteins Pfs230 and Pfs48/45 as potent vaccine targets, opening the possibility of blocking the parasite’s transmission by up to 99.7 percent.

    Commercial deployment of vaccines is also expanding. Novavax, in partnership with Serum Institute of India and Oxford University, announced that its R21/Matrix-M malaria vaccine has sold 20 million doses since its mid-2024 launch, according to the company’s second quarter results released on August 6. The vaccine is addressing urgent needs in malaria-endemic regions, but distribution remains largely concentrated in high-transmission areas, primarily in Africa.

    In the United States, malaria remains rare and travel-related, but new developments have arisen. News outlets including the Spokesman-Review and Vax-Before-Travel report a possible first instance of locally transmitted malaria in Washington State—a woman in Pierce County who has not traveled recently was diagnosed earlier this month. If confirmed, this would be the first known case west of the Rockies, and health officials are investigating and testing local mosquitoes. Generally, 2,000 to 2,500 malaria cases are reported annually in the U.S., almost always tied to travel from countries where malaria transmission is active. While Africa has two malaria vaccines available, as of August 7, 2025, these vaccines are not yet available in the United States.

    This week’s updates underscore both scientific progress and persistent global obstacles in the malaria fight. The rapid advancement of new vaccines and treatments raises hope, but logistical hurdles, funding challenges, and unequal vaccine access continue to complicate the path towards global malaria elimination.
    続きを読む 一部表示
    4 分
  • Groundbreaking Malaria Vaccine Developments: Australian Research Breakthrough and African Manufacturing Strides

    Groundbreaking Malaria Vaccine Developments: Australian Research Breakthrough and African Manufacturing Strides
    2025/08/08
    New developments in malaria research and vaccine innovation have dominated global health news in recent days, with breakthrough findings announced by Australian scientists and landmark advances in vaccine production on the African continent.

    Researchers at the Walter and Eliza Hall Institute of Medical Research in Australia have identified a promising new target for next-generation malaria vaccines, marking a significant leap in efforts to curb the transmission of this deadly disease. Using advanced cryo-electron microscopy, the team captured for the first time the detailed structure of a protein complex essential for the fertilization of the Plasmodium falciparum parasite inside mosquitoes. This insight enabled the development of an mRNA vaccine candidate that blocks the parasite from reproducing, leading to a reported 99.7 percent reduction in malaria transmission during preclinical studies, according to Anadolu Agency. By targeting the fertilization process, this vaccine candidate offers a new approach that, rather than protecting individuals directly, interrupts the cycle of malaria at its source.

    Lead researcher Dr. Melanie Dietrich explained that visualizing the full fertilization complex in its natural form allowed the discovery of a previously unknown critical region, unveiling a powerful new vaccine target. This breakthrough is recognized as a potential game-changer, as malaria continues to kill over 600,000 people annually and affect nearly 300 million worldwide, as recently reported by The Microbiologist and the Walter and Eliza Hall Institute of Medical Research.

    The approach is intended not as a replacement but as a complement to existing malaria vaccines, such as the WHO-recommended R21/Matrix-M vaccine, which targets different parasite stages in humans. The transmission-blocking mRNA vaccine would be deployed alongside these, aiming for comprehensive, multilayered protection and significantly reducing malaria's reach. Colin Pouton, co-developer of the vaccine at Monash Institute of Pharmaceutical Sciences, noted that this new avenue illustrates the broader utility of mRNA technology beyond COVID-19 vaccination efforts, Anadolu Agency reports.

    Meanwhile, Africa is making strides toward vaccine manufacturing independence. Kigali, Rwanda, is preparing for the launch of BioNTech’s modular mRNA vaccine plant, constructed from prefabricated BioNTainers. According to Finn Partners, this facility will focus on producing vaccines against malaria and tuberculosis, promising not just supply for Rwanda but also exports to neighboring countries. The effort, funded at more than $145 million, forms part of a larger strategy for regional vaccine sovereignty and serves as a milestone in Africa’s ambition to control its health future. This builds on recent partnerships, including Sanofi’s agreement with South Africa’s Biovac in 2024 to locally manufacture polio vaccines.

    Elsewhere in Africa, Rwanda is reconsidering its vaccine strategy amid a surprise surge in malaria cases, following years of declining transmission, reports MalariaWorld. The government is now looking closely at vaccine options it had previously declined, seeking to bolster its national malaria response.

    In summary, the past two days have seen unprecedented momentum in malaria vaccine research, with Australian scientists paving the way for a new class of transmission-blocking vaccines and African nations advancing efforts to produce vaccines locally. This convergence of scientific innovation and regional self-sufficiency holds promise for making malaria elimination a realistic global goal.
    続きを読む 一部表示
    4 分